GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing King-Friend Biochemical Pharmaceutical Co Ltd (SHSE:603707) » Definitions » EV-to-EBITDA

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) EV-to-EBITDA : -56.37 (As of May. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nanjing King-Friend Biochemical Pharmaceutical Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nanjing King-Friend Biochemical Pharmaceutical Co's enterprise value is ¥22,213 Mil. Nanjing King-Friend Biochemical Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-394 Mil. Therefore, Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-EBITDA for today is -56.37.

The historical rank and industry rank for Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:

SHSE:603707' s EV-to-EBITDA Range Over the Past 10 Years
Min: -102.42   Med: 27.39   Max: 49.21
Current: -56.37

During the past 11 years, the highest EV-to-EBITDA of Nanjing King-Friend Biochemical Pharmaceutical Co was 49.21. The lowest was -102.42. And the median was 27.39.

SHSE:603707's EV-to-EBITDA is ranked worse than
100% of 715 companies
in the Drug Manufacturers industry
Industry Median: 14.42 vs SHSE:603707: -56.37

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), Nanjing King-Friend Biochemical Pharmaceutical Co's stock price is ¥13.39. Nanjing King-Friend Biochemical Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-0.220. Therefore, Nanjing King-Friend Biochemical Pharmaceutical Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Nanjing King-Friend Biochemical Pharmaceutical Co EV-to-EBITDA Historical Data

The historical data trend for Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing King-Friend Biochemical Pharmaceutical Co EV-to-EBITDA Chart

Nanjing King-Friend Biochemical Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.19 32.89 38.43 22.23 -418.18

Nanjing King-Friend Biochemical Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.47 17.89 18.28 -418.18 -47.42

Competitive Comparison of Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-EBITDA falls into.



Nanjing King-Friend Biochemical Pharmaceutical Co EV-to-EBITDA Calculation

Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=22213.200/-394.028
=-56.37

Nanjing King-Friend Biochemical Pharmaceutical Co's current Enterprise Value is ¥22,213 Mil.
Nanjing King-Friend Biochemical Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-394 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanjing King-Friend Biochemical Pharmaceutical Co  (SHSE:603707) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Nanjing King-Friend Biochemical Pharmaceutical Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.39/-0.220
=At Loss

Nanjing King-Friend Biochemical Pharmaceutical Co's share price for today is ¥13.39.
Nanjing King-Friend Biochemical Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.220.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Nanjing King-Friend Biochemical Pharmaceutical Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Business Description

Traded in Other Exchanges
N/A
Address
1/16 Xuefu Road, Nanjing High-Tech Zone, Nanjing, CHN, 210061
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
Executives
Huang Xi Wei Director
Liu Zu Qing Supervisors
Xie Ju Hua Director
Wu Gui Ping senior management
Tang Yong Qun Director
Qian Xiao Jie senior management

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Headlines

No Headlines